Pegasus Biotech, a global leader in DNA vaccine development, has announced the launch of its groundbreaking BPE plasmid technology. The company claims that this new technology enables the control of when and how DNA is produced, resulting in significantly higher replication levels compared to existing technology.
Dr. Patrick Slaine, who led the development of the BPE plasmid technology, stated that it utilizes a patented origin that can lay dormant during fermentation and trigger replication at high cell densities. This feature allows for more precise and controlled DNA production, making it ideal for applications where cost of goods sold and patient safety are important factors.
The BPE plasmid technology does not use an antibiotic resistance selection marker and contains minimal bacterial sequences, less than 1,000 base pairs. Additionally, it offers enhanced expression levels, with cells transfected with BPE plasmid showing up to 7 times more expression than conventional plasmid backbones.
Pegasus Biotech specializes in ensuring that client projects comply with global regulations and result in commercially viable products. Their services include seed-to-formulation process development and associated analytical development. For more information on Pegasus’ services, visit their website.
According to Daniel Wilson, COO of Pegasus Biotech, this transformational technology will revolutionize the way we approach vaccine and biopharmaceutical development. He emphasized that the project required low cost, minimal bacterial sequences, high expression levels
